Compare International Business Machines Corp (IBM) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

International Business Machines CorpTrade

Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

International Business Machines Corp vs Neurocrine Biosciences Inc — how do they compare? International Business Machines Corp trades at $236.28 (market cap $224.62B), while Neurocrine Biosciences Inc trades at $154.4 (market cap $16.46B). The key difference: International Business Machines Corp is far larger — about 13.6× Neurocrine Biosciences Inc's market cap, and International Business Machines Corp pays a 2.84% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.

	IBM	NBIX
Market Cap	$224.62B	$16.46B
Volume	4,481,527	—
Sector	Technology	Health
52-Week High	$329.23	$185.50
52-Week Low	$205.77	$123.10
Enterprise Value	$281.76B	$16.48B
Dividend Yield	2.84%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

International Business Machines Corp

IBM trades at $236.31, down 0.41% today, with a mixed technical picture showing bearish moving averages but bullish overall signals. Recent earnings beat expectations in Q4 2025 and Q1 2026, with Q2 2026 meeting estimates, while revenue grew to $67.54 billion in 2025. The company secured a $240 million AI deal with Together AI, boosting sentiment despite ongoing securities fraud investigations.

Outlook: IBM's strong profitability and AI growth present upside potential, but legal risks and high valuation ratios pose challenges. The consensus price target of $257.38 suggests moderate growth, supported by institutional buy ratings, though investors should monitor legal developments and competitive pressures in the tech sector.

Neurocrine Biosciences Inc

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

IBM

Big Tech plans $725B AI spend in 2026, but IBM warns revenue may not justify it.24/7 Wall Street · 1 day agoNeutral IBM and Together AI launch first large-scale NVIDIA HGX B300 AI inference cluster on IBM Cloud.PRNewsWire · 1 day agoBullish OpenAI expands Daybreak cyber defense with new GPT-5.6-Cyber model for advanced security tasksTechCrunch · 1 day agoBullish View details →

NBIX

INGREZZA shows significant quality of life and movement improvements in tardive dyskinesia patients after 24 weeks.PRNewsWire · 4 hours agoBullish View details →

About International Business Machines Corp

International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.